雅培将获得Action Pharma的II期急性肾损伤药物的全球权利

Pharmadeals Review Pub Date : 2012-05-14 DOI:10.3833/PDR.V2012I5.1742

Heather Cartwright

{"title":"雅培将获得Action Pharma的II期急性肾损伤药物的全球权利","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1742","DOIUrl":null,"url":null,"abstract":"Abbott is to acquire worldwide development and commercialisation rights to Action Pharma’s AP214, an alpha-MSH (melanocyte-stimulating hormone) peptide derivative in Phase IIb development for the prevention of acute kidney injury associated with major cardiac surgery, for a one-time cash payment of US$110 M. Zealand Pharma, from which Action licensed the SIP® (structure induced probe) peptide modification technology that has been used in the development of AP214, also stands to benefit from the deal.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I5.1742\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abbott is to acquire worldwide development and commercialisation rights to Action Pharma’s AP214, an alpha-MSH (melanocyte-stimulating hormone) peptide derivative in Phase IIb development for the prevention of acute kidney injury associated with major cardiac surgery, for a one-time cash payment of US$110 M. Zealand Pharma, from which Action licensed the SIP® (structure induced probe) peptide modification technology that has been used in the development of AP214, also stands to benefit from the deal.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I5.1742\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I5.1742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

雅培将获得Action Pharma的AP214的全球开发和商业化权利，AP214是一种α - msh(黑色素细胞刺激激素)肽衍生物，处于IIb期开发，用于预防重大心脏手术相关的急性肾损伤。一次性现金支付1.1亿美元，Action Pharma授权了用于AP214开发的SIP®(结构诱导探针)肽修饰技术。也将从这笔交易中受益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug

Abbott is to acquire worldwide development and commercialisation rights to Action Pharma’s AP214, an alpha-MSH (melanocyte-stimulating hormone) peptide derivative in Phase IIb development for the prevention of acute kidney injury associated with major cardiac surgery, for a one-time cash payment of US$110 M. Zealand Pharma, from which Action licensed the SIP® (structure induced probe) peptide modification technology that has been used in the development of AP214, also stands to benefit from the deal.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量